ALLMedicine™ Ulcerative Colitis Center

Dec 3rd, 2021 - Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present final data from OCTAVE Open, an open-label, long-term extension study. The primary objective of OCTAVE Open was to assess the safety ...

Dec 2nd, 2021 - P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.|2021|Oleg K,Anna K,Albina L,Anait B,Dmitriy K,|

Dec 2nd, 2021 - P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.|2021|Oleg K,Sergey K,Anna K,Albina L,Karina N,|

Dec 2nd, 2021 - P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.|2021|Hartman B,Diana H,Casey C,|

Dec 2nd, 2021 - P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.|2021|Jean-Frederic C,Geert D,Peter I,AnnKatrin P,Denesh C,|

Oct 22nd, 2020 - Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 positi...

Mar 29th, 2020 - Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.|2020| ,|

Mar 15th, 2020 - Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|

Jan 17th, 2020 - AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|therapeutic use,standards,diagnosis,immunology,therapy,diagnostic imaging,immunology,p...

Oct 30th, 2019 - Management of ulcerative colitis: summary of updated NICE guidance.|2019|Abdulrazeg O,Li B,Epstein J, ,|drug therapy,methods,therapeutic use,drug therapy,drug therapy,

Nov 25th, 2021 - The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a cocktail of representative probe substrates of cytochr...

Nov 25th, 2021 - Chronic Venous Disease (CVD) is a widespread clinical condition widely spread in the western countries, with a prevalence ranging from 10% in adults younger than 30 years of age to nearly 80% for individuals >70 years of age. CVD clinical manifest...

Nov 25th, 2021 - The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

Nov 24th, 2021 - This is an open-label (both [participants and investigator] know what treatment participants will receive) and multicenter study. The study is divided into 2 parts: Part 1: pharmacokinetics portion (Week 0 to Week 14); Part 2: study extension (Wee...

Nov 24th, 2021 - The purpose of this study is to evaluate the long-term safety and efficacy of BMS-986165 in participants who have previously been enrolled in a BMS-986165 Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.

Nov 30th, 2021 - The Odoribacter splanchnicus strain of human donor-derived bacteria correlated with clinical response to ulcerative colitis in study in which mouse models were colonized with patient-derived strains. Although some recent trials have shown the effe.

Nov 17th, 2021 - Additional analyses of a postmarketing trial that was required after the Food and Drug Administration's approval of the Janus kinase inhibitor tofacitinib (Xeljanz, Xeljanz XR) has identified characteristics of older patients with rheumatoid arthr...

Nov 17th, 2021 - The decision to Initiate biologics early in the treatment of Crohn's disease (CD) and ulcerative colitis (UC) should be based on complication risk, not on the assumption that earlier treatment produces better results, new research suggests. Result...

Nov 15th, 2021 - NEW YORK (Reuters Health) - In patients with inflammatory bowel disease (IBD) who contracted COVID-19 infection, anti-tumor necrosis factor (anti-TNF) therapies were associated with more favorable outcomes than corticosteroids or mesalamine in a s...

Nov 9th, 2021 - NEW YORK (Reuters Health) - Assisted reproductive therapy (ART) is safe in women with inflammatory bowel disease (IBD), with outcomes likely similar in women with ulcerative colitis (UC) and medically managed Crohn's disease (CD) compared with the...